Tempest Therapeutics Reports 100% CR Rate for CAR-T Program TPST-2003 Amidst Going Concern Warning

summarizeSummary

Tempest Therapeutics reported strong interim clinical data for its lead CAR-T program, TPST-2003, with a 100% complete response rate in multiple myeloma patients, alongside year-end 2025 financial results highlighting significant cash burn and a "going concern" warning.

check_boxKey Events

• Positive Clinical Data for TPST-2003

  Interim results from the REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma patients showed a 100% complete response (CR) rate among all six efficacy evaluable patients, with a favorable safety profile.

• Year-End 2025 Financial Results

  The company reported $7.7 million in cash and cash equivalents as of December 31, 2025, down from $30.3 million in 2024, and a net loss of $26.3 million for the year. Research and development expenses decreased due to re-prioritization of efforts.

• Going Concern Warning

  Tempest Therapeutics explicitly stated its need for additional capital to fund planned programs and operations and to continue as a going concern, indicating significant financial challenges.

• Strategic Pipeline Expansion

  The company completed a strategic all-stock acquisition of new dual-targeting CAR-T assets from Factor Bioscience Inc., including TPST-2003.

auto_awesomeAnalysis

Tempest Therapeutics announced highly positive interim clinical data for its lead CAR-T program, TPST-2003, demonstrating a 100% complete response rate in six evaluable patients with relapsed/refractory multiple myeloma and a favorable safety profile. This strong clinical signal is a significant catalyst for a clinical-stage biotechnology company and could attract further investment or partnerships. However, the company's year-end 2025 financial results reveal a precarious financial position, with cash and cash equivalents significantly reduced to $7.7 million and an explicit disclosure of the need for additional capital to continue as a going concern. The financial challenges, including substantial cash burn and cost-cutting measures, present a major risk, but the promising clinical data offers a potential path to overcome these hurdles and validates the company's strategic pipeline expansion.